CellX is a cellular agriculture company focused on cultivated meat, seafood, and mycelium-based ingredients. It aims to provide sustainable, ethical alternatives to animal protein and is expanding into B2B ingredients and licensing.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Latest Price
$124M
IPO, Feb 2022, Perplexity
UpMarket Estimate
$124M
Based on UpMarket valuation model
How to Invest in CellX Through UpMarket
CellX shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Step 01
Verify accredited investor status
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Step 02
Create an UpMarket account
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Step 03
Review available CellX offerings
Full offering memoranda and risk disclosures provided before any commitment is required.
Step 04
Complete subscription documents
Review and sign subscription agreement. All documents handled digitally through the platform.
Step 05
Fund your investment
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Feb 2022
IPO
$15.00
$124M
Why Investors Are Watching CellX
Growth Signal
CellX raised $6.5M Series A+ to fund pilot-scale production
Shanghai-based CellX closed a $6.5 million Series A+ round, bringing total funding to nearly 200 million yuan. The new capital is intended to advance pilot-scale production for its cellular agriculture platform.
Competitive Moat
CellX says it is building a humane, sustainable cell-ag model
CellX describes its mission as creating a sustainable and humane future through cellular agriculture. The company is positioned in alternative protein and lab-grown meat, a niche where process know-how and scale-up execution can create differentiation.
Market Opportunity
CellX operates from Shanghai with 40 staff in a fast-growing niche
CellX is listed as a 2020-founded Shanghai company with about 40 employees on a pre-IPO market profile. Its focus on cellular agriculture places it in a global market tied to climate tech and alternative protein demand.
Interested in CellX stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, CellX is a private company and does not trade on any public stock exchange. Accredited investors can access CellX shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
CellX does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in CellX shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.
Pre-IPO investments carry significant risks. CellX shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of $124M is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
CellX develops cultivated meat, seafood, and mycelium-based ingredients and is valued at $111M, following a $6.5M Series A+ to fund pilot-scale production. Accredited investors can access CellX stock through UpMarket.